News for BeiGene Ltd (spons. ADRs)

Markets Insider Automation 681d

BeiGene earnings preview: what Wall Street is expecting

Benzinga 687d

Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says

Seeking Alpha 692d

BeiGene drug gets positive EMA panel opinion for esophageal cancer

TipRanks 694d

Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and BeiGene (BGNE)

Benzinga 695d

BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View

Benzinga 695d

Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023

TipRanks 696d

Citi Reaffirms Their Buy Rating on BeiGene (BGNE)

Seeking Alpha 698d

Catalyst Watch: Microsoft-Activision Blizzard drama, Splunk event and Nasdaq 100 rebalancing countdown

Seeking Alpha 701d

BeiGene wins FDA review to expand Brukinsa label for lymphoma

TipRanks 701d

BeiGene (BGNE) Receives a Hold from Bank of America Securities

Seeking Alpha 702d

Novartis ends licensing deal with BeiGene

PR Newswire 712d

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

Benzinga 712d

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023

Benzinga 712d

Why This BeiGene Analyst Slashes Forecast By Almost 42%

Benzinga 713d

NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday

TipRanks 713d

Bernstein Sticks to Its Hold Rating for BeiGene (BGNE)

TipRanks 715d

Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BeiGene (BGNE)

PR Newswire 719d

BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

Benzinga 728d

Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Benzinga 728d

Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Seeking Alpha 728d

BTBT, GREE and CIFR among pre-market losers

Seeking Alpha 728d

AbbVie files patent lawsuit over BeiGene’s cancer drug - Bloomberg

Seeking Alpha 728d

Biggest stock movers today: MicroVision, BeiGene and more

TipRanks 729d

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and BeiGene (BGNE)

TipRanks 757d

Bank of America Securities Reaffirms Their Hold Rating on BeiGene (BGNE)

TipRanks 765d

SVB Securities Remains a Buy on BeiGene (BGNE)

TipRanks 769d

Bernstein Sticks to Its Buy Rating for BeiGene (BGNE)

Seeking Alpha 770d

BeiGene Non-GAAP EPS of -$3.34 beats by $0.32, revenue of $447.8M misses by $1.64M

Seeking Alpha 771d

Immix stock slumps ~20% amid interim data for IMX-110 in colorectal cancer

Seeking Alpha 778d

Zymeworks, Jazz in pact over cancer antibody zanidatamab

Seeking Alpha 784d

Novartis, BeiGene tislelizumab meets main goal in gastric/esophagus cancer trial

InvestorPlace 784d

7 Biotech Stocks That Could Cure Your Portfolio Woes

TipRanks 792d

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Zynex (ZYXI) and Legend Biotech (LEGN)

Seeking Alpha 794d

Premier cancer research event, AACR is starting this week; Here is what to expect

TipRanks 809d

J.P. Morgan Analysts Say These 2 Stocks Are Their Top Picks for 2023

TipRanks 811d

5 Best Healthcare Stocks to Invest in Now, According to Analysts

Seeking Alpha 814d

Zymeworks a buy at Wells Fargo on royalty streams, future milestones

TipRanks 834d

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Arcus Biosciences (RCUS) and Karuna Therapeutics (KRTX)

TipRanks 834d

SVB Securities Sticks to Their Buy Rating for BeiGene (BGNE)

TipRanks 834d

Guggenheim Keeps Their Buy Rating on BeiGene (BGNE)

TipRanks 835d

Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Henry Schein (HSIC) and BeiGene (BGNE)

Benzinga 836d

Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk

Seeking Alpha 836d

BeiGene GAAP EPADS of -$4.29 misses by $0.10, revenue of $380.1M misses by $8.07M

Seeking Alpha 838d

BeiGene Q4 2022 Earnings Preview

Seeking Alpha 857d

Quebec to fund BeiGene's Brukinsa to treat rare blood cancer

Seeking Alpha 861d

Roche CEO drags Arcus, iTeos lower after comments on cancer trial

TipRanks 869d

Morgan Stanley Reaffirms Their Buy Rating on BeiGene (BGNE)

Benzinga 873d

4 Analysts Have This to Say About BeiGene

Benzinga 874d

Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday

TipRanks 874d

Analysts Are Bullish on These Healthcare Stocks: Johnson & Johnson (JNJ), BeiGene (BGNE)

	
		OSZAR »